Af­ter be­ing re­peat­ed­ly jilt­ed, this biotech was swept off its feet in a race to ASH: In­side Mer­ck­'s $2.7B Ar­Qule buy­out

Over a pe­ri­od of more than a year, the ex­ecs at Ar­Qule had one fling af­ter the next with po­ten­tial part­ners, but ei­ther got left at the deal al­tar or were jilt­ed by cheap suit­ors. Then Mer­ck stepped in and swept them up with a short, in­tense round of ne­go­ti­a­tions in the lead-up to ASH.

Ar­Qule had plen­ty of dis­ap­point­ments to con­tend with along the way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER